Table 4

Effect of surveillance programme (irrespective of the purpose of the cancer diagnosing EGD) on mortality risk of patients with Barrett's oesophagus and newly diagnosed oesophageal adenocarcinoma (EAC)

HR95% CI
BE surveillance programme versus non-surveillance
All EAC cases (n=207/424; 106/246 surveillance and 101/178 non-surveillance)
 Unadjusted0.650.49 to 0.85
 Adjusted* (without stage or treatment)0.630.47 to 0.84
 Adjusted (including stage)0.900.66 to 1.22
 Adjusted (including stage and treatment)0.890.65 to 1.22
EAC-related mortality (n=187/424; 94/246 surveillance and 93/178 non-surveillance)
 Unadjusted0.630.47 to 0.84
 Adjusted* (without stage or treatment)0.600.45 to 0.82
 Adjusted (including stage)0.870.63 to 1.21
 Adjusted (including stage and treatment)0.870.63 to 1.20
  • *Adjusted for year of EAC diagnosis, age, race, propensity of EGD, comorbidity score, total number of VA visit, GI clinic visit.

  • EGD, oesophagogastroduodenoscopy; VA, Veteran Affairs.